NCT04949425View on ClinicalTrials.gov

A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours

PHASE1TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

September 13, 2021

Primary Completion Date

April 21, 2022

Study Completion Date

April 21, 2022

Conditions
Advanced Solid Tumours
Interventions
DRUG

Adavosertib

Patients will receive Adavosertib orally.

Trial Locations (2)

75230

Research Site, Dallas

M20 4BX

Research Site, Manchester

Sponsors

Lead Sponsor

AstraZeneca

Collaborators (1)

Parexel
All Listed Sponsors
collaborator

Parexel

INDUSTRY

lead

AstraZeneca

INDUSTRY